KR101120337B1 - 항당뇨제 및 항비만제로서 유용한 치환된 헤테로시클릭유도체 및 방법 - Google Patents
항당뇨제 및 항비만제로서 유용한 치환된 헤테로시클릭유도체 및 방법 Download PDFInfo
- Publication number
- KR101120337B1 KR101120337B1 KR1020057000362A KR20057000362A KR101120337B1 KR 101120337 B1 KR101120337 B1 KR 101120337B1 KR 1020057000362 A KR1020057000362 A KR 1020057000362A KR 20057000362 A KR20057000362 A KR 20057000362A KR 101120337 B1 KR101120337 B1 KR 101120337B1
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- compound
- vacuo
- etoac
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CB*([C@]1C(C)(C)C(*C)*C(C)(*)*1)=* Chemical compound CB*([C@]1C(C)(C)C(*C)*C(C)(*)*1)=* 0.000 description 7
- ZGYAZKWPGZAERP-SFHVURJKSA-N C[C@@H](c(cc1)ccc1OCc1n[o]c(-c2ccccc2)n1)N(CC(O)=O)C(Oc(cc1)ccc1OC)=O Chemical compound C[C@@H](c(cc1)ccc1OCc1n[o]c(-c2ccccc2)n1)N(CC(O)=O)C(Oc(cc1)ccc1OC)=O ZGYAZKWPGZAERP-SFHVURJKSA-N 0.000 description 2
- BEHGSBHGGFGHNK-UHFFFAOYSA-O CC(C(CCOc1cc(C=O)ccc1)=N)=[NH2+] Chemical compound CC(C(CCOc1cc(C=O)ccc1)=N)=[NH2+] BEHGSBHGGFGHNK-UHFFFAOYSA-O 0.000 description 1
- SPNBYIKLOPPDMJ-UHFFFAOYSA-N CC(C(COc1ccc(CN(CC(O)=O)C(Oc(cc2)ccc2OC)=O)cc1)=N)=[N-] Chemical compound CC(C(COc1ccc(CN(CC(O)=O)C(Oc(cc2)ccc2OC)=O)cc1)=N)=[N-] SPNBYIKLOPPDMJ-UHFFFAOYSA-N 0.000 description 1
- QFJVGMISEWVWHQ-UHFFFAOYSA-N CC(C(COc1cccc(CN(CC(O)=O)C(Oc(cc2)ccc2OC)=O)c1)=N)=N Chemical compound CC(C(COc1cccc(CN(CC(O)=O)C(Oc(cc2)ccc2OC)=O)c1)=N)=N QFJVGMISEWVWHQ-UHFFFAOYSA-N 0.000 description 1
- QEGBHZPYASQVSS-KRWDZBQOSA-N CC(C)COC(N(CC(O)=O)[C@@H](C)c(cc1)ccc1OCc1n[o]c(-c2ccccc2)n1)=O Chemical compound CC(C)COC(N(CC(O)=O)[C@@H](C)c(cc1)ccc1OCc1n[o]c(-c2ccccc2)n1)=O QEGBHZPYASQVSS-KRWDZBQOSA-N 0.000 description 1
- PHOYXRFFTLCMFV-GOSISDBHSA-N CC(C)COC(N(CC(O)=O)[C@H](C)c(cc1)ccc1OCc1n[o]c(-c2ccc(C)cc2)n1)=O Chemical compound CC(C)COC(N(CC(O)=O)[C@H](C)c(cc1)ccc1OCc1n[o]c(-c2ccc(C)cc2)n1)=O PHOYXRFFTLCMFV-GOSISDBHSA-N 0.000 description 1
- PHOAKNSKNQZSNX-ZDUSSCGKSA-N CC(C)COC(N(CC(OC)=O)[C@@H](C)c(cc1)ccc1OC/C(/N)=N/O)=O Chemical compound CC(C)COC(N(CC(OC)=O)[C@@H](C)c(cc1)ccc1OC/C(/N)=N/O)=O PHOAKNSKNQZSNX-ZDUSSCGKSA-N 0.000 description 1
- ZISXNBTWRDBEFS-UHFFFAOYSA-N COC(CN(Cc1cc(OCCBr)ccc1)c1cc(OC(F)(F)F)ccc1)=O Chemical compound COC(CN(Cc1cc(OCCBr)ccc1)c1cc(OC(F)(F)F)ccc1)=O ZISXNBTWRDBEFS-UHFFFAOYSA-N 0.000 description 1
- XJNBORAMUADJQM-VIFPVBQESA-N C[C@@H](c(cc1)ccc1O)N(CC(OC)=O)C(OC)=O Chemical compound C[C@@H](c(cc1)ccc1O)N(CC(OC)=O)C(OC)=O XJNBORAMUADJQM-VIFPVBQESA-N 0.000 description 1
- GBXNLCBCMJKELF-SFHVURJKSA-N C[C@@H](c(cc1)ccc1OCCc1n[o]c(-c(cc2)ccc2OC(F)(F)F)n1)N(CC(O)=O)C(Oc(cc1)ccc1OC)=O Chemical compound C[C@@H](c(cc1)ccc1OCCc1n[o]c(-c(cc2)ccc2OC(F)(F)F)n1)N(CC(O)=O)C(Oc(cc1)ccc1OC)=O GBXNLCBCMJKELF-SFHVURJKSA-N 0.000 description 1
- WYSJIAAIMNTVGG-FQEVSTJZSA-N C[C@@H](c(cc1)ccc1OCCc1n[o]c(-c2ccc(C)cc2)n1)N(CC(O)=O)C(Oc(cc1)ccc1OC)=O Chemical compound C[C@@H](c(cc1)ccc1OCCc1n[o]c(-c2ccc(C)cc2)n1)N(CC(O)=O)C(Oc(cc1)ccc1OC)=O WYSJIAAIMNTVGG-FQEVSTJZSA-N 0.000 description 1
- BGMARGHMMCVSDF-AWEZNQCLSA-N C[C@@H](c(cc1)ccc1OCc1n[o]c(-c2ccccc2)n1)N(CC(O)=O)C(OC)=O Chemical compound C[C@@H](c(cc1)ccc1OCc1n[o]c(-c2ccccc2)n1)N(CC(O)=O)C(OC)=O BGMARGHMMCVSDF-AWEZNQCLSA-N 0.000 description 1
- TXCFNYAOHWYBBG-UHFFFAOYSA-N Cc1c(CCO)[o]c(-c2ccccc2)n1 Chemical compound Cc1c(CCO)[o]c(-c2ccccc2)n1 TXCFNYAOHWYBBG-UHFFFAOYSA-N 0.000 description 1
- SBQPDLGIWJRKBS-UHFFFAOYSA-N Cc1c[nH]c(S)n1 Chemical compound Cc1c[nH]c(S)n1 SBQPDLGIWJRKBS-UHFFFAOYSA-N 0.000 description 1
- WBPIYKDVDGLHJE-UHFFFAOYSA-N OC(CN(Cc1cc(OCCc2n[o]c(-c3ccccc3)n2)ccc1)c1cc(OC(F)(F)F)ccc1)=O Chemical compound OC(CN(Cc1cc(OCCc2n[o]c(-c3ccccc3)n2)ccc1)c1cc(OC(F)(F)F)ccc1)=O WBPIYKDVDGLHJE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39455302P | 2002-07-09 | 2002-07-09 | |
| US60/394,553 | 2002-07-09 | ||
| PCT/US2003/021331 WO2004004655A2 (en) | 2002-07-09 | 2003-07-08 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20050025951A KR20050025951A (ko) | 2005-03-14 |
| KR101120337B1 true KR101120337B1 (ko) | 2012-02-29 |
Family
ID=30115733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057000362A Expired - Fee Related KR101120337B1 (ko) | 2002-07-09 | 2003-07-08 | 항당뇨제 및 항비만제로서 유용한 치환된 헤테로시클릭유도체 및 방법 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6875782B2 (https=) |
| EP (1) | EP1531810B1 (https=) |
| JP (1) | JP4541883B2 (https=) |
| KR (1) | KR101120337B1 (https=) |
| CN (1) | CN1665500A (https=) |
| AT (1) | ATE543497T1 (https=) |
| AU (1) | AU2003248861B2 (https=) |
| BR (1) | BR0312503A (https=) |
| CA (1) | CA2490972C (https=) |
| ES (1) | ES2380319T3 (https=) |
| GE (1) | GEP20084475B (https=) |
| HR (1) | HRP20050001A2 (https=) |
| IL (1) | IL165809A (https=) |
| IS (1) | IS7629A (https=) |
| MX (1) | MXPA05000279A (https=) |
| NO (1) | NO329328B1 (https=) |
| NZ (1) | NZ537251A (https=) |
| PL (1) | PL375230A1 (https=) |
| RS (1) | RS20050002A (https=) |
| RU (1) | RU2325381C2 (https=) |
| UA (1) | UA79296C2 (https=) |
| WO (1) | WO2004004655A2 (https=) |
| ZA (1) | ZA200500029B (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012733A2 (en) * | 2002-08-01 | 2004-02-12 | Neurosearch A/S | Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| US20060183897A1 (en) * | 2003-03-18 | 2006-08-17 | Chakravarty Prasun K | Biaryl substituted triazoles as sodium channel blockers |
| US7550590B2 (en) | 2003-03-25 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2004103993A1 (en) | 2003-05-14 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| KR20060041309A (ko) | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| FR2861301B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| FR2861303A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR2861300B1 (fr) * | 2003-10-24 | 2008-07-11 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
| FR2861302A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique. |
| WO2006128058A2 (en) | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| CN1882327A (zh) * | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| US7932268B2 (en) | 2004-03-05 | 2011-04-26 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
| US20060014785A1 (en) * | 2004-05-25 | 2006-01-19 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
| AU2005247473A1 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Substituted triazoles as modulators of PPAR and methods of their preparation |
| WO2006032042A2 (en) * | 2004-09-15 | 2006-03-23 | Regeneron Pharmaceuticals, Inc. | Us of cntf or a cntf derivative in combination with a further compound for the preparation of medicament for the treatment of obesity |
| WO2006039334A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
| EP1866298A2 (en) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| WO2006117743A1 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Substituted aromatic compounds as antidiabetic agents |
| WO2006128056A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| FR2889191A1 (fr) * | 2005-07-28 | 2007-02-02 | Cerep Sa | Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1 |
| GEP20135838B (en) | 2005-09-14 | 2013-06-10 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors usage at diabetes treatment |
| CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
| EP1951220A2 (en) * | 2005-10-18 | 2008-08-06 | Aegerion Pharmaceuticals | Compositions for lowering serum cholesterol and/or triglycerides |
| JP2009538892A (ja) * | 2006-05-30 | 2009-11-12 | アストラゼネカ アクチボラグ | アセチル補酵素ａジアシルグリセロールアシルトランスフェラーゼの阻害薬としての置換５−フェニルアミノ−１，３，４−オキサジアゾール−２−イルカルボニルアミノ−４−フェノキシ−シクロヘキサンカルボン酸 |
| WO2007138304A1 (en) * | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
| US20080009534A1 (en) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| CA2673290A1 (en) * | 2006-12-21 | 2008-07-03 | Aegerion Pharmaceuticals, Inc. | Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN103694195B (zh) * | 2013-09-18 | 2016-04-06 | 华东师范大学 | 芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途 |
| EP3190103A1 (en) * | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| CA3044059A1 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| US11707472B2 (en) | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| KR101943382B1 (ko) | 2017-09-19 | 2019-01-29 | 오토텔릭바이오 주식회사 | Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물 |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| GB201810486D0 (en) * | 2018-06-26 | 2018-08-08 | Imperial Innovations Ltd | Natural killer cells |
| KR102131359B1 (ko) * | 2018-09-07 | 2020-07-07 | 오토텔릭바이오 주식회사 | 안정성이 향상된 의약 조성물 |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US20230285376A1 (en) | 2020-07-29 | 2023-09-14 | Amryt Pharmaceuticals Inc. | Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001021602A1 (en) * | 1999-09-22 | 2001-03-29 | Bristol-Myers Squibb Company | Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995018130A1 (en) | 1993-12-28 | 1995-07-06 | Meiji Seika Kabushiki Kaisha | Tricyclic benzazepine and benzothiazepine derivatives |
| JPH10501222A (ja) * | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
| WO1997000258A1 (en) | 1995-06-15 | 1997-01-03 | Meiji Seika Kabushiki Kaisha | Tricyclic benzazepine compounds |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| JP3215048B2 (ja) * | 1996-04-03 | 2001-10-02 | 日本たばこ産業株式会社 | プロピオン酸誘導体及びその用途 |
| JPH1067759A (ja) | 1996-06-20 | 1998-03-10 | Sankyo Co Ltd | 除草性アゾール誘導体 |
| JPH11263775A (ja) | 1997-09-08 | 1999-09-28 | Sankyo Co Ltd | ヒドロキシアニリン誘導体 |
| DK1026167T3 (da) | 1997-09-29 | 2003-05-26 | Meiji Seika Kaisha | Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler |
| ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| FR2778314B1 (fr) | 1998-05-07 | 2002-06-14 | Rhone Poulenc Agrochimie | Composition fongicide synergique comprenant un compose analogue de la strobilurine |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| US6506781B1 (en) | 1999-09-08 | 2003-01-14 | Smithkline Beecham Corporation | Oxazole PPAR antagonist |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| HK1045991B (en) | 1999-11-10 | 2004-12-10 | Takeda Pharmaceutical Company Limited | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| GB0029974D0 (en) * | 2000-12-08 | 2001-01-24 | Glaxo Group Ltd | Chemical compounds |
-
2003
- 2003-07-08 BR BRPI0312503-3A patent/BR0312503A/pt not_active IP Right Cessation
- 2003-07-08 CN CN038160382A patent/CN1665500A/zh active Pending
- 2003-07-08 HR HR20050001A patent/HRP20050001A2/hr not_active Application Discontinuation
- 2003-07-08 PL PL03375230A patent/PL375230A1/xx not_active Application Discontinuation
- 2003-07-08 EP EP03763345A patent/EP1531810B1/en not_active Expired - Lifetime
- 2003-07-08 RU RU2005103395/04A patent/RU2325381C2/ru not_active IP Right Cessation
- 2003-07-08 US US10/616,283 patent/US6875782B2/en not_active Expired - Lifetime
- 2003-07-08 JP JP2004520018A patent/JP4541883B2/ja not_active Expired - Fee Related
- 2003-07-08 CA CA2490972A patent/CA2490972C/en not_active Expired - Fee Related
- 2003-07-08 KR KR1020057000362A patent/KR101120337B1/ko not_active Expired - Fee Related
- 2003-07-08 AU AU2003248861A patent/AU2003248861B2/en not_active Ceased
- 2003-07-08 AT AT03763345T patent/ATE543497T1/de active
- 2003-07-08 MX MXPA05000279A patent/MXPA05000279A/es active IP Right Grant
- 2003-07-08 RS YUP-2005/0002A patent/RS20050002A/sr unknown
- 2003-07-08 ES ES03763345T patent/ES2380319T3/es not_active Expired - Lifetime
- 2003-07-08 NZ NZ537251A patent/NZ537251A/en not_active IP Right Cessation
- 2003-07-08 GE GEAP8617A patent/GEP20084475B/en unknown
- 2003-07-08 WO PCT/US2003/021331 patent/WO2004004655A2/en not_active Ceased
- 2003-08-07 UA UAA200501187A patent/UA79296C2/uk unknown
-
2004
- 2004-12-16 IL IL165809A patent/IL165809A/en not_active IP Right Cessation
- 2004-12-17 US US11/016,183 patent/US7507757B2/en not_active Expired - Lifetime
- 2004-12-17 NO NO20045529A patent/NO329328B1/no not_active IP Right Cessation
-
2005
- 2005-01-03 ZA ZA200500029A patent/ZA200500029B/xx unknown
- 2005-01-05 IS IS7629A patent/IS7629A/is unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001021602A1 (en) * | 1999-09-22 | 2001-03-29 | Bristol-Myers Squibb Company | Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101120337B1 (ko) | 항당뇨제 및 항비만제로서 유용한 치환된 헤테로시클릭유도체 및 방법 | |
| EP1401433B1 (en) | Azole acid derivatives, alone or in combination, for treating diabetes and dyslipidemias; and for treating malignant diseases | |
| US6673815B2 (en) | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | |
| JP4332315B2 (ja) | 抗糖尿病剤および抗肥満剤として有用な置換酸誘導体および方法 | |
| US6727271B2 (en) | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | |
| AU2002310141B2 (en) | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | |
| EP1939188A1 (en) | Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents | |
| AU2002310141A1 (en) | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PJ0201 | Trial against decision of rejection |
St.27 status event code: A-3-3-V10-V11-apl-PJ0201 |
|
| PB0901 | Examination by re-examination before a trial |
St.27 status event code: A-6-3-E10-E12-rex-PB0901 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
St.27 status event code: A-3-4-F10-F13-rex-PB0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20150127 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20150127 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |